文献速递泌尿生殖与妇科肿瘤放疗

超低分次放疗与中等低分次放疗在前列腺癌治疗中的急性毒性比较:一项随机试验

Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-04-10

本随机试验将80例中高危局限性前列腺癌患者分配至中等低分次放疗(MHF,70 Gy/28次)或超低分次放疗(UHF,36.25 Gy/5次),对78例患者分析至少6个月随访的早期毒性及生活质量。两组≥3级毒性(MHF 8% vs UHF 2%,P=.235)和≥2级毒性(MHF 36% vs UHF 24%,P=.235)均无统计学显著差异,生活质量各领域最小重要变化比例亦无显著差异。结论认为UHF耐受良好,至治疗后6个月UHF与MHF在毒性和生活质量变化上无显著差异。

要点

  • UHF(36.25 Gy/5次)与MHF(70 Gy/28次)在≥3级毒性上无统计学显著差异(MHF 8% vs UHF 2%,P=.235)。
  • ≥2级毒性两组亦无显著差异(MHF 36% vs UHF 24%,P=.235)。
  • 生活质量Incontinence、Irritative/Obstructive、Bowel领域最小重要变化比例两组均无显著差异。

核心结论

  • UHF放疗用于前列腺癌耐受良好,至治疗后6个月UHF与MHF在毒性和生活质量变化上无显著差异。

研究设计与样本

  • 随机试验,纳入80例中高危局限性前列腺癌患者,随机分配至MHF(70 Gy/28次每日分割)或UHF(36.25 Gy/5次每周分割)。
  • 2例退出放疗,最终对78例患者进行分析,所有患者随访至少6个月。
  • 采用Common Terminology Criteria for Adverse Events及Radiation Therapy Oncology Group/Subjective, Objective, Management, Analytic量表分析早期毒性,采用Expanded Prostate Inventory Composite问卷评估患者报告的生活质量。

主要发现

  • 两组关键患者和疾病特征均衡,但UHF组基线泌尿功能统计学显著更差(International Prostate Symptom Score >7:UHF 68% vs MHF 36%,P=.004)。
  • ≥3级毒性:MHF 8% vs UHF 2%(P=.235),无统计学显著差异。
  • ≥2级毒性:MHF 36% vs UHF 24%(P=.235),无统计学显著差异。
  • 生活质量Incontinence领域最小重要变化:MHF 36% vs UHF 33%(P=.746),无显著差异。
  • 生活质量Irritative/Obstructive领域最小重要变化:MHF 56% vs UHF 74%(P=.074),Bowel领域:MHF 58% vs UHF 52%(P=.508),均无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report on the early toxic effects and quality of life of localized prostate cancer radiation therapy in a randomized trial comparing moderate hypofractionation (MHF) with ultrahypofractionation (UHF). METHODS AND MATERIALS: We randomized patients with intermediate- to high-risk localized prostate cancer to radiation therapy with MHF (70 Gy in 28 daily fractions) or UHF (36.25 Gy in 5 weekly fractions). We analyzed early toxic effects (using Common Terminology Criteria for Adverse Events and Radiation Therapy Oncology Group/Subjective, Objective, Management, Analytic scales) and patient-reported quality of life (using the Expanded Prostate Inventory Composite questionnaire) when all patients had at least 6 months of follow-up. RESULTS: We randomized 80 participants. Two patients withdrew from radiation therapy. We ran analysis on results for 78 patients. The 2 arms were balanced in key patient and disease characteristics, except for a statistically worse baseline urinary function in the UHF arm (International Prostate Symptom Score >7: 68% vs 36%, P = .004). There were no statistically significant differences between the 2 arms in grade 3 or grade 2 toxic effects: grade ≥3 MHF 8%, UHF 2% (P = .235); grade ≥2 MHF 36%, UHF 24% (P = .235). There were also no significant differences in percentages of patients with a "minimal important change" of quality of life in the Incontinence (MHF 36%, UHF 33%; P = .746), Irritative/Obstructive (MHF 56%, UHF 74%; P = .074), or Bowel domains (MHF 58%, UHF 52%; P = .508) on the Expanded Prostate Inventory Composite questionnaire. CONCLUSIONS: UHF radiation therapy for prostate cancer is well tolerated, and there were no significant differences in toxic effects and quality of life changes between UHF and MHF up to 6 months after treatment in the current trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kwan W, Bahl G, Kim D, et al. Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35417763. doi:10.1016/j.ijrobp.2022.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。